{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:08:21Z","timestamp":1776092901970,"version":"3.50.1"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA-192937"],"award-info":[{"award-number":["P50CA-192937"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA-210105"],"award-info":[{"award-number":["R35CA-210105"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["TRP 6644-22"],"award-info":[{"award-number":["TRP 6644-22"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD020056"],"award-info":[{"award-number":["S10OD020056"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA013696"],"award-info":[{"award-number":["P30CA013696"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["Restart Award"],"award-info":[{"award-number":["Restart Award"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) includes the activated B cell\u2013like (ABC) and germinal center B cell\u2013like (GCB) subtypes, which differ in cell of origin, genetics, and clinical response. By screening the subtype-specific activity of 211 drugs approved or in active clinical development for other diseases, we identified inhibitors of nicotinamide phosphoribosyl transferase (NAMPTi) as active in a subset of GCB-DLBCL in vitro and in vivo. We validated three chemically distinct NAMPTis for their on-target activity based on biochemical and genetic rescue approaches and found the ratio between NAMPT and PARP1 RNA levels was predictive of NAMPTi sensitivity across DLBCL subtypes. Notably, the NAMPT:PARP1 transcript ratio predicts higher antitumor activity in BCL2-translocated GCB-DLBCL. Accordingly, pharmacologic and genetic inhibition of BCL2 was potently synergistic with NAMPT blockade. These data support the inhibition of NAMPT as a therapeutically relevant strategy for BCL2-translocated DLBCLs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Targeted therapies have emerged for the ABC subtype of DLBCL, but not for the GCB subtype, despite the evidence of a significant subset of high-risk cases. We identify a drug that specifically targets a subset of GCB-DLBCL and provide preclinical evidence for BCL2 translocations as biomarkers for their identification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0020","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T08:40:05Z","timestamp":1722933605000},"page":"417-427","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Repurposing NAMPT Inhibitors for Germinal Center B Cell\u2013Like Diffuse Large B-Cell Lymphoma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4615-0883","authenticated-orcid":false,"given":"Claudio","family":"Scuoppo","sequence":"first","affiliation":[{"name":"1Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"2Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7995-4920","authenticated-orcid":false,"given":"Bowen","family":"Cai","sequence":"additional","affiliation":[{"name":"1Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-2882","authenticated-orcid":false,"given":"Kenneth","family":"Ofori","sequence":"additional","affiliation":[{"name":"1Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"2Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-8191","authenticated-orcid":false,"given":"Hanna","family":"Scholze","sequence":"additional","affiliation":[{"name":"1Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6927-5390","authenticated-orcid":false,"given":"Rahul","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2258-6490","authenticated-orcid":false,"given":"Angelo","family":"D\u2019Alessandro","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9316-6039","authenticated-orcid":false,"given":"Katia","family":"Basso","sequence":"additional","affiliation":[{"name":"1Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"2Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-7370","authenticated-orcid":false,"given":"Laura","family":"Pasqualucci","sequence":"additional","affiliation":[{"name":"1Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"2Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"4Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-8826","authenticated-orcid":false,"given":"Riccardo","family":"Dalla-Favera","sequence":"additional","affiliation":[{"name":"1Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"2Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"4Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"5Department of Genetics and Development, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."},{"name":"6Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"2026041310182797800_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026041310182797800_bib2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19\u2212directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"2026041310182797800_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/jpm11050355","article-title":"Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas","volume":"11","author":"Salvaris","year":"2021","journal-title":"J Pers Med"},{"key":"2026041310182797800_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","article-title":"Idelalisib in the management of lymphoma","volume":"128","author":"Cheah","year":"2016","journal-title":"Blood"},{"key":"2026041310182797800_bib5","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"2026041310182797800_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ccr.2013.12.012","article-title":"SnapShot: diffuse large B cell lymphoma","volume":"25","author":"Pasqualucci","year":"2014","journal-title":"Cancer Cell"},{"key":"2026041310182797800_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"2026041310182797800_bib8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"2026041310182797800_bib9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041310182797800_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.semcancer.2020.02.003","article-title":"Turning liabilities into opportunities: off-target based drug repurposing in cancer","volume":"68","author":"Palve","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"2026041310182797800_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"2026041310182797800_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026041310182797800_bib13","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2026041310182797800_bib14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"2026041310182797800_bib15","doi-asserted-by":"crossref","first-page":"16981","DOI":"10.1073\/pnas.1905239116","article-title":"Repurposing dasatinib for diffuse large B cell lymphoma","volume":"116","author":"Scuoppo","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026041310182797800_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fonc.2018.00622","article-title":"NAD metabolism in cancer therapeutics","volume":"8","author":"Yaku","year":"2018","journal-title":"Front Oncol"},{"key":"2026041310182797800_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1042\/BST20180417","article-title":"Keeping the balance in NAD metabolism","volume":"47","author":"Str\u00f8mland","year":"2019","journal-title":"Biochem Soc Trans"},{"key":"2026041310182797800_bib18","doi-asserted-by":"crossref","first-page":"v125","DOI":"10.1093\/annonc\/mdx367.008","article-title":"A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL","volume":"28","author":"Naing","year":"2017","journal-title":"Annal Oncol"},{"key":"2026041310182797800_bib19","doi-asserted-by":"crossref","first-page":"16451","DOI":"10.18632\/oncotarget.24731","article-title":"Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment","volume":"9","author":"Ogino","year":"2018","journal-title":"Oncotarget"},{"key":"2026041310182797800_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arr.2018.05.006","article-title":"NAD metabolism: implications in aging and longevity","volume":"47","author":"Yaku","year":"2018","journal-title":"Ageing Res Rev"},{"key":"2026041310182797800_bib21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"key":"2026041310182797800_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2026041310182797800_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccell.2016.06.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice","volume":"30","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"key":"2026041310182797800_bib24","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.annonc.2020.05.016","article-title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3\u20135) treated with front-line R-CODOX-M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial","volume":"31","author":"McMillan","year":"2020","journal-title":"Ann Oncol"},{"key":"2026041310182797800_bib25","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1158\/1078-0432.CCR-16-0630","article-title":"Dual NAMPT and BTK targeting leads to synergistic killing of Waldenstr\u00f6m macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status","volume":"22","author":"Cea","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026041310182797800_bib26","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","article-title":"The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies","volume":"113","author":"Nahimana","year":"2009","journal-title":"Blood"},{"key":"2026041310182797800_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/cancers14010160","article-title":"PAK4 and NA","volume":"14","author":"Khan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026041310182797800_bib28","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-16-3079","article-title":"Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair","volume":"77","author":"Piacente","year":"2017","journal-title":"Cancer Res"},{"key":"2026041310182797800_bib29","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"key":"2026041310182797800_bib30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"2026041310182797800_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"2026041310182797800_bib32","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.2951","article-title":"Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing","volume":"32","author":"Heckl","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2026041310182797800_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41592-020-0850-8","article-title":"Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles","volume":"17","author":"Michlits","year":"2020","journal-title":"Nat Methods"},{"key":"2026041310182797800_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3324\/haematol.2017.178608","article-title":"Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage","volume":"103","author":"Nemkov","year":"2018","journal-title":"Haematologica"},{"key":"2026041310182797800_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41586-022-04906-8","article-title":"Super-enhancer hypermutation alters oncogene expression in B cell lymphoma","volume":"607","author":"Bal","year":"2022","journal-title":"Nature"},{"key":"2026041310182797800_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2026041310182797800_bib37","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"2026041310182797800_bib38","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","article-title":"The sva package for removing batch effects and other unwanted variation in high-throughput experiments","volume":"28","author":"Leek","year":"2012","journal-title":"Bioinformatics"},{"key":"2026041310182797800_bib39","doi-asserted-by":"crossref","first-page":"e20200483","DOI":"10.1084\/jem.20200483","article-title":"Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome","volume":"217","author":"Holmes","year":"2020","journal-title":"J Exp Med"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0020\/3483140\/bcd-24-0020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0020\/3508086\/bcd-24-0020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/6\/417\/3509508\/bcd-24-0020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/6\/417\/3509508\/bcd-24-0020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:18:40Z","timestamp":1776089920000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/6\/417\/749227\/Repurposing-NAMPT-Inhibitors-for-Germinal-Center-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8,5]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0020","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.27434063","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434060","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434072","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434069","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434078","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434054","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7520327","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]}}}